Notably, Sema4C was also found to induce ID1 and ID3 transcriptional regulators in triple-negative breast cancer cells, through the enhancement of TGFbeta/BMP signaling; this pathway has been previously implicated in the partial EMT reversion phenotype observed in late stages of the metastatic process 25, which further identifies Sema4C as a relevant driver of breast cancer metastatic progression. Here, SEMA4C is linked to breast carcinoma.